US FDA Role In Biomanufacturing Initiative Largely Packages Ongoing Works
Executive Summary
The White House ‘Biotechnology’ initiative is very broadly focused, with non-health sectors receiving the bulk of the attention. The US FDA’s role is small – but it could further boost attention to efforts to encourage adoption of advanced manufacturing.
You may also be interested in...
COVID-19 Outlook: Variants, Boosters, And Being ‘Worse Off’ For Next Pathogens
US FDA’s Peter Marks, Pfizer’s Mikael Dolsten and other experts discuss what is being done to prepare for the future, worries about higher fatality rates, and what 2023 might look like.
Cross-Strait Taiwan Tensions, COVID, And Clinical Trials: An Interview With TLC President Yeh
A recent survey showed healthcare as among the sectors US companies were most concerned about amid the ongoing China-US tensions over Taiwan. But how do biotech firms on the island itself view the current situation? We spoke to the president of one amid Taiwan’s imminent reopening.
US FDA Limits GMP Exemption For ‘N of 1’ Investigational New Drugs
Agency drafts guidance on how to apply requirements for chemistry, manufacturing and controls, and for good manufacturing practices, to bespoke antisense nucleotides.